ClinicalTrials.gg
Status unknownNCT04073550Updated Aug 29, 2019

Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer

A Phase 3 interventional study of Anlotinib and Placebos in Small Cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-29.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2019), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing anlotinib in Small Cell Lung Carcinoma — 15 open to participants now, 16 under way, 2 of them phase 3. anlotinib · Small Cell Lung Carcinoma.

Planned enrollment
3rd of 35
184 · median 40
Started
2019
with 7 others
Phase 3
4 of 35
2 open now
Registered
10th of 35
by date
Lead sponsor
5 of 35
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 35 studies testing anlotinib in Small Cell Lung Carcinoma, this one is the 3rd largest by planned enrollment, is one of 8 that started in 2019, is one of 4 in phase 3, and was the 10th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

15 of the 35 studies testing anlotinib in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

About anlotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing anlotinib in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant inhibitory activities.

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Small cell lung cancer patients.
  2. The clinical stage at baseline is extensive.
  3. A .
  4. Disease progression.
  5. ≥ 18 years old; (ECOG) performance status of 0 to 1; ≥ 3 months.
  6. Adequate laboratory indicators.
  7. No pregnant or breastfeeding women, and a negative pregnancy test.
  8. Understood and signed an form.

Exclusion criteria

Exclusion Criteria:

  1. Has used topotecan and anlotinib hydrochloride capsules.
  2. Has used other anti-angiogenic drugs and immunologically targeted drugs.
  3. Has other malignant tumors within 5 years.
  4. Symptomatic .
  5. Has a variety of factors affecting oral medications.
  6. Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage.
  7. Spinal cord compression.
  8. Has received radiotherapy, chemotherapy, surgery less than 4 weeks before randomization.
  9. Adverse events caused by previous treatment did not recover to grade 1.
  10. Has received major surgical treatment within 4 weeks before randomization.
  11. Arteriovenous thrombosis occurred within 6 months.
  12. Has drug abuse history that unable to abstain from or mental disorders.
  13. Has severe or uncontrolled disease.
  14. Participated in other clinical trials within 4 weeks.
  15. Tumor invades the large blood vessels.
  16. Daily hemoptysis ≥2.5 mL within 1 month before the first dose.
  17. According to the investigators' judgement.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Anlotinib hydrochloride capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.

    Drug: Anlotinib · Drug: Topotecan

  • Placebo comparator
    Placebo group

    Anlotinib hydrochloride placebo given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) and topotecan 1.5mg/m2 IV d1-5.

    Drug: Placebos · Drug: Topotecan

Interventions

  • A multi-target receptor tyrosine kinase inhibitor.

  • DrugPlacebos

    Anlotinib blank analog capsule.

  • A topoisomerase I inhibitor.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) evaluated by IRC

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause; IRC defined as Independent Review Committee.

    Time frame: up to 24 months

Secondary outcomes

  1. Progression Free Survival (PFS) evaluated by investigator

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: up to 24 months

  2. Overall survival (OS)

    OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: up to 24 months

  3. Overall Response Rate (ORR)

    Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR).

    Time frame: up to 24 months

  4. Disease Control Rate (DCR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 24 months

  5. Duration of Overall Response (DOR)

    The time when the patient first achieved complete or partial remission to disease progression.

    Time frame: up to 24 months

  6. PFS rate at month 6

    The percentage of PFS at month 6.

    Time frame: up to 6 months

  7. OS rate at month 6

    The percentage of OS at month 6.

    Time frame: up to 6 months

  8. OS rate at month 12

    The percentage of OS at month 12.

    Time frame: up to 12 months

  9. The efficacy of intracranial lesions

    To evaluate the efficacy of of intracranial lesions.

    Time frame: up to 24 months

  10. Adverse Event (AE)

    Safety data

    Time frame: up to 24 months

  11. Serious Adverse Event (SAE)

    Safety data

    Time frame: up to 24 months

  12. Abnormal laboratory test index

    Safety data

    Time frame: up to 24 months

07

Study locations

2 sites
  • Beijing Cancer Hospital
    Beijing, Beijing 100083, China
    • Ziping Wang, Doctor · Contactwangzp2007@126.com · 010-88196456
    • Ziping Wang, Doctor · Principal investigator
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100083, China
    • Yuankai Shi, Master · Contactsyuankaipumc@126.com · 010-87788293
    • Yuankai Shi, Master · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2019; primary completion for Jul 2021, 21 months later.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 21 months is below that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2019
First posted
Aug 29, 2019
StartEst.
Oct 31, 2019
Primary completionEst.
Jul 31, 2021
CompletionEst.
Jul 31, 2022
Last update
Aug 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04073550
Responsible party
Sponsor
First posted
Aug 29, 2019
Start date
Oct 31, 2019 (estimated)
Primary completion
Jul 31, 2021 (estimated)
Completion
Jul 31, 2022 (estimated)
Last update
Aug 29, 2019

Study contacts

YuanKai Shi, Master
Contact
syuankaipumc@126.com
010-87788293

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anlotinib

Start the discussion